|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience显示文摘AIM To evaluate the long-term treatment outcomes of tenofovir therapy in patients in a real world Australian tertiary care setting.METHODS We performed a retrospective analysis of treatment outcomes among treatment-na?ve and treatment-experienced patients receiving a minimum 3 mo tenofovir therapy through St Vincent's Hospital Melbourne, Australia. We included patients receiving tenofovir [tenofovir disoproxil fumarate(TDF)] monotherapy, as well as patients treated with TDF in combination with a second antiviral agent. Patients were excluded if they demonstrated human immune-deficiency virus/hepatitis C virus/hepatitis delta virus coinfection or were less than 18 years of age. We considered virological and biochemicalresponse, as well as safety outcomes. Virological response was determined by measurement of hepatitis B virus(HBV) DNA using sensitive assays; biochemical response was determined via serum liver function tests; histological response was determined from liver biopsy and fibroscan; safety analysis focused on glomerular renal function and bone mineral density. The primary efficacy endpoint was complete virological suppression over time, defined by HBV DNA < 20 IU/m L. Secondary efficacy endpoints included rates of biochemical response, and HB e antigen(HBe Ag)/HB surface antigen loss and seroconversion over time.RESULTS Ninety-two patients were identified who fulfilled the enrolment criteria. Median follow-up was 26 mo(range 3-114). Mean age was 46(24-78) years, 64(70%) were male and 77(84%) were of Asian origin. 55(60%) patients were treatment-na?ve and 62 patients(67%) were HBe Ag-negative. Complete virological suppression was achieved by 45/65(71%) patients at 12 mo, 37/46(80%) at 24 mo and 25/28(89%) at 36 mo. Partial virological response(HBV DNA 20-2000 IU/m L) was achieved by 89/92(96.7%) of patients. Multivariate analysis showed a significant relationship between virological suppression at end of follow-up and baseline HBV DNA level(OR = 0.897, 95%CI: 0.833-0.967, P = 0.0046) and HBe Ag positive status(OR = 0.373, 95%CI: 0.183-0.762, P = 0.0069). There was no difference in response comparing treatment-na?ve and treatment-experienced patients. Three episodes of virological breakthrough occurred in the setting of noncompliance. Tenofovir therapy was well tolerated.CONCLUSION Tenofovir is an efficacious, safe and well-tolerated treatment in an Australian real-world tertiary care setting. Our data are similar to the reported experience from registration trials. | Grace C Lovett Tin Nguyen David M Iser Jacinta A Holmes Robert Chen Barbara Demediuk Gideon Shaw Sally J Bell Paul V Desmond Alexander J Thompson | 2017 | World Journal of Hepatology2017，9，1： | 7 |
| 2 | Celiac plexus neurolysis in the management of unresectable pancreatic cancer:When and how?显示文摘Pancreatic cancer is the second most common abdominal cancer in North America with an estimated 20%resectability at diagnosis,and overall 5-year survival of 5%.Pain is common in pancreatic cancer patients with 70%-80%suffering substantial pain.Celiac plexus neurolysis(CPN)is a technique that can potentially improve pain control in pancreatic cancer while preventing further escalation of opioid consumption.CPN is performed by injecting absolute alcohol into the celiac plexus neural network of ganglia.This review sets out to explore the current status of CPN in non-resectable pancreatic cancer.We will examine:(1)the efficacy and safety of percutaneous-CPN and endoscopic ultrasound guided-CPN;(2)specific technique modifications including bilateral(vs central)injections and celiac ganglia neurolysis;and(3)the issue of CPN timing,early at pancreatic cancer diagnosis vs traditional late use as salvage therapy. | Jonathan M Wyse Yen-I Chen Anand V Sahai | 2014 | World Journal of Gastroenterology2014，20，9： | 4 |
| 3 | Perioperative risk factors associated with delayed graft function following deceased donor kidney transplantation:A retrospective,single center study显示文摘BACKGROUND There is an abundant need to increase the availability of deceased donor kidney transplantation(DDKT)to address the high incidence of kidney failure.Challenges exist in the utilization of higher risk donor organs into what appears to be increasingly complex recipients;thus the identification of modifiable risk factors associated with poor outcomes is paramount.AIM To identify risk factors associated with delayed graft function(DGF).METHODS Consecutive adults undergoing DDKT between January 2016 and July 2017 were identified with a study population of 294 patients.The primary outcome was the occurrence of DGF.RESULTS The incidence of DGF was 27%.Under logistic regression,eight independent risk factors for DGF were identified including recipient body mass index≥30 kg/m^(2),baseline mean arterial pressure<110 mmHg,intraoperative phenylephrine administration,cold storage time≥16 h,donation after cardiac death,donor history of coronary artery disease,donor terminal creatinine≥1.9 mg/dL,and a hypothermic machine perfusion(HMP)pump resistance≥0.23 mmHg/mL/min.CONCLUSION We delineate the association between DGF and recipient characteristics of preinduction mean arterial pressure below 110 mmHg,metabolic syndrome,donorspecific risk factors,HMP pump parameters,and intraoperative use of phenylephrine. | Nicholas V Mendez Yehuda Raveh Joshua J Livingstone Gaetano Ciancio Giselle Guerra George W Burke III Vadim B Shatz Fouad G Souki Linda J Chen Mahmoud Morsi Jose M Figueiro Tony M Ibrahim Werviston L DeFaria Ramona Nicolau-Raducu | 2021 | World Journal of Transplantation2021，11，4： | 2 |
| 4 | 强化与标准降压治疗对脑卒中亚型的影响显示文摘在收缩压干预试验(systolic blood pressure intervention trial, SPRINT)中,各治疗组的脑卒中发生比例差异无统计学意义,但脑卒中亚型的病因不同,可能对强化降压治疗的反应不同。SPRINT纳入患者(n=9 361)随机分为目标收缩压<120 mm Hg(1 mm Hg=0.133 kPa)的强化治疗与目标收缩压<140 mm Hg的标准治疗组。 | Wright CB Auchus AP Lerner A Ambrosius WT Ay H Bates JT Chen J Meschia JF Pancholi S Papademetriou V Rastogi A Sweeney M Willard JJ Yee J Oparil S 赵狄(摘译) 郑武洪(审校) | 2021 | 中华高血压杂志2021，29，3： | 2 |
| 5 | IL 28 B genotype is not useful for predicting treatment outcome in A sian chronic hepatitis B patients treated with pegylated interferon‐α显示文摘 | Jacinta A Holmes Tin Nguyen Dilip Ratnam Neel M Heerasing Jane V Tehan Sara Bonanzinga Anouk Dev Sally Bell Stephen Pianko Robert Chen Kumar Visvanathan Rachel Hammond David Iser Ferry Rusli William Sievert Paul V Desmond D Scott Bowden Alexander J Thomps | 2013 | J Gastroenterol Hepatol2013，，5： | 2 |
| 6 | Lipoxygenase is involved in the control of potato tuber development 显示文摘 | Kolomiets M V Hannapel D J Chen H | 2001 | Plant Cell2001，13，： | 1 |
| 7 | Interfacial Phenomena controlling particle morphology of composite latex显示文摘 | Chen Y C Dimornie V EI-Aasser M S | | 0，，： | 1 |
| 8 | Preparation and comparison of supported gold nanocatalysts on anatase, brookite, rutile, and P25 polymorphs of TiO2 for catalytic oxidation of CO 显示文摘 | Yan Wenfu Chen Bei Mahurin S M Schwartz V Mullins D R Lupini R Andrew Pennycook S J Dai Sheng Overbury S H | 2005 | Journal of Physical Chemistry B2005，109，10： | 1 |
| 9 | Experimental Study of Thin Steel-Plate Shear Walls Under Cyclic Loading显示文摘 | Caccese V Elgaaly M Chen R | | 0，，02： | 1 |
| 10 | Electrocatalysis and simultaneous detection of dopamine and ascorbic acid using poly(3,4-ethylenedioxy)thiophene film modified electrodes显示文摘 | Vasantha V S Chen S M | 2006 | J Electroanal Chem2006，592，1： | 1 |
| 11 | Cell-permeable peptides induce dose-and length-dependent cytotoxic effects 显示文摘 | Cardozo AK Buchillier V Mathieu M Chen J Ortis F Ladriere L | 2007 | Biochim Biophys Acta2007，1768，9： | 1 |
| 12 | Bioeffects of myocardial con-trast microbubble destruction by echocardiography显示文摘 | Chen S Kroll M H Shohet R V | 2002 | Echocardio-graphy2002，19，6： | 1 |
| 13 | Hydrogen peroxide dose dependent induction of cell death or hypertrophy incardiomyocytes显示文摘 | Chen Q M Tu V C Wu Y | 2000 | Arch Biochem Biophys2000，373，1： | 1 |
| 14 | Mobile visual search 显示文摘 | GIROD B CHANDRASEKHAR V CHEN D M | 2011 | Signal Processing Magazine IEEE2011，28，4： | 1 |
| 15 | A classification of unruptured middle cerebral artery bifurcation aneurysms that can help in choice of clipping technique显示文摘 | Kumar M V Karagiozov K L Chen L Imizu S Yoneda M Watabe T | 2007 | Minim Invasive Neurosurg2007，50，： | 1 |
| 16 | Experimental study of thin steel-plate shear walls under cyclic load 显示文摘 | Caccese V Elgaaly M Chen R | 1993 | Journal of Structural Engineering1993，119，2： | 1 |
| 17 | FDA-approved drug labeling for the study of drug-induced liver injury显示文摘 | Chen M Vijay V Shi Q | 2011 | Drug Discou Today2011，16，15： | 1 |
| 18 | Some tuning rules for PI^λ controllers robust to gain or time constant changes 显示文摘 | Monje C A Vinagre B M Chen Y Q Feliu V | 2004 | Nonlinear Dynamics (S0924-090X)2004，38，： | 1 |
| 19 | Small,clonally variant antigens expressed on the surface of the Plasmodium falciparuminfected erythrecyte are encoded by the rif gone family and are the target of human immune reponses显示文摘 | Fernandez V Hommel M Chen Q | 1999 | J Exp Med1999，190，10： | 1 |
| 20 | Role of the Fas/Fas ligand pathway in apoptotic cell death induced by the human T cell lymphotropic virus type I Tax transactivator显示文摘 | Chen X Zachar V Zdravkovic M | 1997 | J Gen Vir- ol1997，78，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员